(Q42694701)

English

Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB).

scientific article published on December 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB). (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

C Grassi

1

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

L Casali

2

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

E Curti

3

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

M Tellarini

4

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

C Lazzaro

5

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

G Schito

6

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

SMART Study Group. Studio Multicentrico con Moxifloxacina nel Trattamento delle Riacutizzazioni de Bronchite Cronica

7

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

publication date

1 December 2002

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Journal of Chemotherapy

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

597-608

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Quality of life in acute exacerbation of chronic bronchitis: results from a German population study.

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2002.14.6.597

21 January 2018

The patient's burden: physical and psychological effects of acute exacerbations of chronic bronchitis.

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2002.14.6.597

21 January 2018

Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2002.14.6.597

21 January 2018

Treatment outcomes in acute exacerbations of chronic bronchitis: comparison of macrolides and moxifloxacin from the patient perspective

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2002.14.6.597

21 January 2018

Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2002.14.6.597

21 January 2018

The role of antimicrobial therapy in acute exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2002.14.6.597

21 January 2018

Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999.

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2002.14.6.597

21 January 2018

Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacin

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2002.14.6.597

21 January 2018

Moxifloxacin in acute exacerbations of chronic bronchitis: clinical evaluation and assessment by patients

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2002.14.6.597

21 January 2018

Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2002.14.6.597

21 January 2018

Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2002.14.6.597

21 January 2018

Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis.

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2002.14.6.597

21 January 2018

Outpatient parenteral antimicrobial-drug therapy

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2002.14.6.597

21 January 2018

Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2002.14.6.597

21 January 2018

Effect of moxifloxacin on secretion of cytokines by human monocytes stimulated with lipopolysaccharide

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2002.14.6.597

21 January 2018

Immunomodulatory effects of moxifloxacin in comparison to ciprofloxacin and G-CSF in a murine model of cyclophosphamide-induced leukopenia

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2002.14.6.597

21 January 2018

Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2002.14.6.597

21 January 2018

Parenteral cephalosporin therapy in ambulatory care: advantages and disadvantages

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2002.14.6.597

21 January 2018

Identifiers

10.1179/JOC.2002.14.6.597

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42694701&oldid=2047707981"